# NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.

> **NCT00318266** · — · COMPLETED · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 73 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DEVICE:** Nuclear Matrix Protein 22 Urine sample kit

## Key facts

- **NCT ID:** NCT00318266
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2017-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318266, "NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00318266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*